JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Bhananker, S. M. Articles by Bishop, M. J. Search for Related Content PubMed PubMed Citation Articles by Bhananker, S. M. Articles by Bishop, M. J. Related Collections Complications Pharmacology

---

ECONOMICS, EDUCATION, AND HEALTH SYSTEMS RESEARCH

The Risk of Anaphylactic Reactions to Rocuronium in the United States Is Comparable to That of Vecuronium: An Analysis of Food and Drug Administration Reporting of Adverse Events

Sanjay M. Bhananker, MD, FRCA^*, James T. O’Donnell, PharmD, FCP, John R. Salemi, BS, and Michael J. Bishop, MD^*

*Department of Anesthesiology, University of Washington School of Medicine, Seattle, WA; Department of Pharmacology, Rush Medical College, Chicago, IL; Pharmaconsultant, Inc., Palatine, IL; and Department of Veterans Affairs and the Departments of Anesthesiology and Medicine (adjunct, Pulmonary and Critical Care), University of Washington School of Medicine, Seattle, WA

Address correspondence and reprint requests to Sanjay M. Bhananker, MD, FRCA, Department of Anesthesiology, Harborview Medical Center, 325 9th Avenue, Seattle, WA 98104. Address electronic mail to: sbhanank{at}u.washington.edu.

Published reports from France and Norway suggest a frequent incidence of anaphylaxis to rocuronium and have raised concerns about its safety. We hypothesized that the Food and Drug Administration Adverse Event Reporting System could be used to confirm whether there has been an unusual incidence of anaphylactic events for rocuronium in the United States (U.S.) and whether the reporting patterns differ within and outside of the U.S.. We queried the Food and Drug Administration Adverse Event Reporting System for 1999 through the first quarter of 2002 for all adverse events for the drugs rocuronium and vecuronium and then searched on the terms considered to represent possible anaphylaxis using proprietary software. We compared the frequency of these terms in data both for rocuronium and vecuronium. We then assessed the occurrence of reports of anaphylaxis-related terms in reports from the U.S. compared with reports originating outside of the U.S.. For rocuronium, the database contained 311 reports, 166 domestic and 145 from foreign sources. Fifty percent of the foreign reports contained an anaphylaxis term versus 20% of the domestic reports (P < 0.001). For vecuronium, the comparable figures were 17% and 19% (not significant) and the total number of reports was 243. The incidence of the reports containing anaphylaxis terms did not differ between vecuronium and rocuronium in the U.S. but were significantly different for foreign reports (P < 0.001). These data confirm that U.S. anesthesia providers have not observed a significant difference in anaphylactic reactions between the two commonly used intermediate-acting muscle relaxants and suggest that frequency of reports of anaphylaxis may be significantly influenced by the area from which the reports originate.

This article has been cited by other articles:

				F. Donati and B. Plaud Tracheal intubation: optimal conditions, vocal cord damage, and allergy/Intubation tracheale: conditions optimales, lesions laryngees et allergie Can J Anesth, October 1, 2008; 55(10): 663 - 669. [Full Text] [PDF]

				L. Meng and E. L. Williams Case report: Treatment of rocuronium-induced anaphylactic shock with vasopressin: [Presentation de cas: traitement d'un choc anaphylactique provoque par le rocuronium avec de la vasopressine] Can J Anesth, July 1, 2008; 55(7): 437 - 440. [Abstract] [Full Text] [PDF]

				J. H. Levy and N. F. Adkinson Jr Anaphylaxis During Cardiac Surgery: Implications for Clinicians Anesth. Analg., February 1, 2008; 106(2): 392 - 403. [Abstract] [Full Text] [PDF]

				P. M. Mertes, A. B. Guttormsen, T. Harboe, S. G. O. Johansson, E. Florvaag, B. Husum, L. H. Garvey, M. Kroigaard, L. Gramstad, K. T. Kvande, et al. Can Spontaneous Adverse Event Reporting Systems Really Be Used to Compare Rates of Adverse Events Between Drugs? Anesth. Analg., February 1, 2007; 104(2): 471 - 472. [Full Text] [PDF]

Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999